![David H. Peyton](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David H. Peyton
Corporate Officer/Principal bei Portland State University
Profil
David H.
Peyton is the founder of DesignMedix, Inc. He is currently a Professor at Portland State University since 1987.
He completed his undergraduate degree at Abilene Christian University and his doctorate at the University of California, Santa Barbara.
Aktive Positionen von David H. Peyton
Unternehmen | Position | Beginn |
---|---|---|
Portland State University | Corporate Officer/Principal | 30.10.2009 |
Ehemalige bekannte Positionen von David H. Peyton
Unternehmen | Position | Ende |
---|---|---|
DesignMedix, Inc.
![]() DesignMedix, Inc. Pharmaceuticals: MajorHealth Technology DesignMedix, Inc. develops drugs to overcome drug-resistant diseases. Its pipeline includes RCQ anti-malaria drugs, modified acridone and anti-bacterial drugs. The firm is a drug development company, which develops drugs to overcome drug resistance with a focus on curing malaria in Oregon. It develops drugs to address the large medical need caused by the rapid rise in drug resistance in multiple diseases. The company was founded by Sandra Lee Shotwell, David H. Peyton and Lynnor B. Stevenson in 2006 and is headquartered in Portland, OR. | Gründer | - |
Ausbildung von David H. Peyton
Abilene Christian University | Undergraduate Degree |
University of California, Santa Barbara | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
DesignMedix, Inc.
![]() DesignMedix, Inc. Pharmaceuticals: MajorHealth Technology DesignMedix, Inc. develops drugs to overcome drug-resistant diseases. Its pipeline includes RCQ anti-malaria drugs, modified acridone and anti-bacterial drugs. The firm is a drug development company, which develops drugs to overcome drug resistance with a focus on curing malaria in Oregon. It develops drugs to address the large medical need caused by the rapid rise in drug resistance in multiple diseases. The company was founded by Sandra Lee Shotwell, David H. Peyton and Lynnor B. Stevenson in 2006 and is headquartered in Portland, OR. | Health Technology |